PROZAC WEEKLY
FLUOXETINE HYDROCHLORIDE
Approval overview PROZAC WEEKLY is listed in Drugs@FDA under application 021235 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient FLUOXETINE HYDROCHLORIDE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor LILLY Submission history Latest submission status date: 2017-03-24 00:00:00.
Structured Monograph
Clinical summary
Approval overview PROZAC WEEKLY is listed in Drugs@FDA under application 021235 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FLUOXETINE HYDROCHLORIDE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor LILLY Submission history Latest submission status date: 2017-03-24 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.